Academics at Uppsala University are offering the chance to name an experimental cancer drug with a donation of about £1 million towards researching the drug, the Financial Times reported on 31 August.
The Oncolytic Virus Fund has been set up to help to cover the trial costs of launch the world’s first human trial of an engineered virus that targets neuroendocrine cancer. “To have the world’s first neuroendocrine cancer-targeting virus named in your honour (or in the honour of anyone you chose) requires a donation of one million pounds”, states the fund’s website.
This article on Research Professional News is only available to Research Professional or Pivot-RP users.
Research Professional users can log in and view the article via this link
Pivot-RP users can log in and view the article via this link.